

### AMENDMENTS TO THE CLAIMS

1. (Cancelled)

2. (Currently amended) ~~The A drug combination~~ for proliferating animal natural killer cells ~~according to claim 1 which comprises lactoferrin as a first agent and Toll-like receptor ligand as a second agent, wherein the first agent is administered every day comprises divided doses for 5 to 10 days in an amount of 10 to 2000 mg/day/kg body weight in terms of the amount of lactoferrin, and the second agent is administered 5 to 2 days before the completion of the administration of the first agent comprises one dose in an amount of 10 to 1000 µg/day/kg body weight in terms of the amount of the Toll-like receptor ligand.~~

3. (Currently amended) The drug combination for proliferating animal natural killer cells according to claim ~~1~~2, wherein the dosage form of the first agent containing comprising lactoferrin is ~~orally administered for oral administration~~, and the dosage form of the second agent containing comprising the Toll-like receptor ligand is ~~intraperitoneally administered for intraperitoneal administration~~.

4. (Currently amended) The drug combination for proliferating animal natural killer cells according to claim ~~1~~2, wherein the Toll-like receptor ligand is polyinosinic-polycytidylic acid.

5. (Withdrawn-Currently amended) A method for proliferating natural killer cells in an animal, which comprises administering lactoferrin ~~and a Toll-like receptor ligand~~ the drug combination of claim 2 to the an animal.

6. (Withdrawn) The method for proliferating natural killer cells according to claim 5, wherein lactoferrin is administered every day for 5 to 10 days in an amount of 10 to 2000 mg/day/kg body weight, and the Toll-like receptor ligand is administered 5 to 2 days before the completion of administration of lactoferrin in an amount of 10 to 1000 µg/day/kg body weight.

7. (Withdrawn) The method for proliferating natural killer cells according to claim 5, wherein lactoferrin is orally administered, and the Toll-like receptor ligand is intraperitoneally administered.

8. (Withdrawn) The method for proliferating natural killer cells according to claim 5, wherein the Toll-like receptor ligand is polyinosinic-polycytidylic acid.

9. (Withdrawn-Currently amended) A method for producing natural killer cells, which comprises administering ~~lactoferrin and a Toll-like receptor ligand~~ the drug combination of claim 2 to an animal, and collecting natural killer cells from the animal.

10. (Withdrawn) The method for producing natural killer cells according to claim 9, wherein lactoferrin is administered every day for 5 to 10 days to the animal in an amount of 10 to 2000 mg/day/kg body weight, the Toll-like receptor ligand is administered 5 to 2 days before the completion of administration of lactoferrin in an amount of 10 to 1000 µg/day/kg body weight, and natural killer cells are collected from the animal.

11. (Withdrawn) The method for producing natural killer cells according to claim 9, wherein lactoferrin is orally administered, the Toll-like receptor ligand is intraperitoneally administered, and natural killer cells are collected from the peritoneal cavity.

12. (Withdrawn) The method for producing natural killer cells according to claim 9, wherein the Toll-like receptor ligand is polyinosinic-polycytidylic acid.

13-17. (Cancelled)

18. (Withdrawn-Currently amended) A method of producing ~~a drug for proliferating animal natural killer cells~~ the drug combination of claim 2, which comprises packaging a first agent containing lactoferrin and a second agent containing a Toll-like receptor ligand, wherein the first agent and the second agent are separately packaged.

19. (Withdrawn) The method according to claim 18, wherein the amount of lactoferrin is 10 to 2000 mg/day/kg body weight, and the amount of the Toll-like receptor ligand is 10 to 1000 µg/day/kg body weight.

20. (Withdrawn) The method according to claim 18, wherein the first agent containing lactoferrin is packaged for oral administration, and the second agent containing a Toll-like receptor ligand is packaged for intraperitoneal administration.

21. (Withdrawn) The method according to claim 18, wherein the Toll-like receptor ligand is polyinosinic-polycytidylic acid.

22. (New) The drug combination for proliferating animal natural killer cells according to claim 3, wherein the Toll-like receptor ligand is polyinosinic-polycytidylic acid.